China NMPA Grants Priority Review for Ascentage Pharma’s Lisaftoclax, a Novel Bcl-2 Inhibitor for r/r CLL/SLL
Ascentage Pharma, an international biopharmaceutical company dedicated to discovering, developing, and commercializing innovative treatments addressing worldwide unmet medical needs, particularly in cancer, has announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has accepted […]